Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Duoperone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.59 |
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.59 |
| ▸ | DRD1 known ✓ | P21728 | 3/20 | 0.59 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.59 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.59 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.59 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.59 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.59 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.59 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.59 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.59 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.59 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.59 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.59 |
| ▸ | MTOR known ✓ | P42345 | 2/20 | 0.59 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.59 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.59 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.59 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.59 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duoperone SCHEMBL121485 | 1.00 | FPR2 (0.64) | FPR2RAD52LMNAMAPTCYP3A4 | |
| Duoperone SCHEMBL29694381 | 0.95 | FPR2 (0.70) | FPR2RAD52LMNAMAPTCYP3A4 | |
| Duoperone SCHEMBL2109141 | 0.95 | FPR2 (0.70) | FPR2RAD52LMNAMAPTCYP3A4 | |
| Fumaric Acid SCHEMBL11746586 | 0.90 | CYP2D6 (0.57) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fumaric Acid SCHEMBL9677296 | 0.87 | LMNA (0.54) | RAD52LMNAMAPTCYP3A4MAPK1 | |
| Fumaric Acid SCHEMBL9677289 | 0.87 | LMNA (0.54) | RAD52LMNAMAPTCYP3A4MAPK1 | |
| SCHEMBL11746346 | 0.85 | HTR2A (0.61) | LMNACYP3A4MAPK1USP2DRD2 | |
| SCHEMBL11750190 | 0.83 | DRD2 (0.70) | FPR2LMNACYP3A4MAPK1USP2 | |
| SCHEMBL11743885 | 0.83 | DRD2 (0.73) | FPR2RAD52LMNAMAPTCYP3A4 | |
| Fluphenazine SCHEMBL565707 | 0.83 | LMNA (0.85) | FPR2RAD52LMNAMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-25 | — | — | US | disclosed |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-10995374-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3692989-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | Afecta Pharmaceuticals, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-20200199679-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA | 2020-06-25 | — | — | US | disclosed |
| US-10619209-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190249255-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-08-15 | — | — | US | disclosed |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | LUITPOLD PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| EP-1158973-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6323236-B2 | PSYCHOLOGICAL DISORDERS | UNIVERSITY OF CINCINNATI | 2001-11-27 | — | — | US | disclosed |
| US-20010023254-A1 | Psychological disorders | CINCINNATI, UNIVERSITY OF | 2001-09-20 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10619209-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | DRD2 23/4885HRH1 2879/4885DRD1 40/4885 |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | DRD2 23/4885HRH1 2879/4885DRD1 40/4885 |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | FABP7, FADS2, ALOX5 | DRD2 1420/4885HRH1 2347/4885DRD1 1884/4885 |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | DRD2 23/4885HRH1 2879/4885DRD1 40/4885 |
| US-20190249255-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | SLC6A4, SLC6A3, SLC6A2 | DRD2 31/4885HRH1 2659/4885DRD1 58/4885 |
| US-20200199679-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | DRD2 23/4885HRH1 2879/4885DRD1 40/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | DRD2 2041/4885HRH1 1088/4885DRD1 2497/4885 |
| US-10995374-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | DRD2 23/4885HRH1 2879/4885DRD1 40/4885 |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | DRD2 23/4885HRH1 2879/4885DRD1 40/4885 |
| US-20010023254-A1 | Psychological disorders | DRD2, DRD3, DRD1 | DRD2 1/4885HRH1 402/4885DRD1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.